NCT03336294

Brief Summary

P31 nuclear magnetic resonance (RMN) Spectroscopy (SRM P31) has currently being poorly used in the field of sarcopenia. The aim of the CAMUS study is to investigate the feasibility a protocol of SRM P31 at rest, during and after a standardized physical task. The secondary objective is to compare the metabolism of tyhe skeletal muscle tissue assessed by SRM P31 in young and older individuals. A pilot study, cross-sectional study will be conducted. Ten healthy sedentary 70+ years males and 10 sedentary 25 to 30 years old male will be included. Level of physical activity, physical performances, will be assessed at baseline. RMN (T1; tractography and SRM P31) will be performed. SRM P31 will be performed at rest, during and after an exhausting muscle task at 70% 1-RM. Feasibility will be judged on the rate of valuable variables recorded (\>90%) inorganic phosphate (iP), phosphocreatine (PCr) and isoform of adenosine triphosphate (ATP : alfa, beta, gamma).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 7, 2014

Completed
3.8 years until next milestone

First Posted

Study publicly available on registry

November 8, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

July 16, 2019

Status Verified

July 1, 2019

Enrollment Period

4.8 years

First QC Date

January 7, 2014

Last Update Submit

July 15, 2019

Conditions

Sarcopenia

Keywords

SarcopeniaMuscle strengthSRM P31Phosphocreatine

Outcome Measures

Primary Outcomes (2)

  • SRM P31 assessment

    Feasibility of a protocol of SRM P31 at rest, during and after a standardized physical task defined by a composite criteria : the rate of valuable variables recorded (\>90%) inorganic phosphate (iP), phosphocreatine (PCr) and isoform of ATP (alfa, beta, gamma) on the spectre.

    Change of SRM P31 between Before and during a standardized physical task

  • SRM P31 assessment

    Feasibility of a protocol of SRM P31 at rest, during and after a standardized physical task defined by a composite criteria : the rate of valuable variables recorded (\>90%) inorganic phosphate (iP), phosphocreatine (PCr) and isoform of ATP (alfa, beta, gamma) on the spectre.

    Change of SRM P31 between during and after a standardized physical task

Secondary Outcomes (2)

  • T1; tractography and SRM P31 comparison between young and older sedentary adults

    Change between Before and during a standardized physical task

  • T1; tractography and SRM P31 comparison between young and older sedentary adults

    Change between during and after a standardized physical task

Study Arms (2)

Old group

OTHER

Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.

Radiation: SRM P31

Young group

OTHER

Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.

Radiation: SRM P31

Interventions

SRM P31RADIATION

All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.

Old groupYoung group

Eligibility Criteria

Age25 Years - 99 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Old group : 70+ years males
  • Young group : 25 to 30 years males
  • Sedentary males in the 2 groups
  • Informed consent

You may not qualify if:

  • Contraindication to perform a RMN

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Toulouse

Toulouse, 31300, France

Location

Related Publications (2)

  • Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, Vellas B, Grandjean H. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc. 2003 Aug;51(8):1120-4. doi: 10.1046/j.1532-5415.2003.51362.x.

    PMID: 12890076BACKGROUND

  • Bourdel-Marchasson I, Joseph PA, Dehail P, Biran M, Faux P, Rainfray M, Emeriau JP, Canioni P, Thiaudiere E. Functional and metabolic early changes in calf muscle occurring during nutritional repletion in malnourished elderly patients. Am J Clin Nutr. 2001 Apr;73(4):832-8. doi: 10.1093/ajcn/73.4.832.

    PMID: 11273861BACKGROUND

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Yves ROLLAND, MD; PHD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2014

First Posted

November 8, 2017

Study Start

April 1, 2013

Primary Completion

December 31, 2017

Study Completion

December 31, 2017

Last Updated

July 16, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)